|
Getting your Trinity Audio player ready...
|
Investors following the rapidly growing Alzheimer’s disease, Artificial Intelligence (AI), and biotechnology sectors now have an opportunity to hear directly from IGC Pharma, Inc. (NYSE American: IGC) CEO Ram Mukunda in a new interview on The Street Reports Podcast, where he discusses the Company’s clinical progress, AI initiatives, and long-term strategy.
During the interview, Mukunda highlights IGC Pharma’s lead Phase 2 Alzheimer’s drug candidate, IGC-AD1, which is being evaluated in the ongoing CALMA clinical trial for agitation associated with Alzheimer’s dementia. The Company recently reached its previously announced target enrollment of 146 patients and is completing limited over-enrollment before patient follow-up, database lock, and topline analysis.
Alongside IGC Pharma, Inc. (NYSE: IGC), investors are also monitoring trading activity in Edible Garden Inc. (NASDAQ: EDBL), Vivakor, Inc. (NASDAQ: VIVK), Baiya International Group Inc. (NASDAQ: BIYA), and Canaan Inc. (NASDAQ: CAN) as emerging growth companies attracting investor interest across the Artificial Intelligence, Biotechnology, Energy, Agriculture, and Digital Infrastructure sectors.
The discussion also explores IGC Pharma’s growing investment in Artificial Intelligence, including its proprietary Agentic Harmonization Assistant (AHA) platform. In internal testing, AHA reduced Alzheimer’s research data processing time by approximately 90%, helping researchers organize complex biomedical data and potentially accelerating drug discovery, clinical research, and precision medicine initiatives. Listen to Podcast Now!
IGC Pharma is also preparing to showcase AHA at the Alzheimer’s Association International Conference (AAIC) 2026 in London, where the Company expects to demonstrate how AI can improve biomedical data integration and support faster pharmaceutical research.
Beyond IGC-AD1, IGC Pharma is advancing a pipeline of Alzheimer’s therapeutic candidates, including TGR-63, while expanding AI-enabled technologies designed to support machine learning, clinical trial optimization, and healthcare analytics.
Recent developments have continued to strengthen investor interest. Independent research firm Ascendiant Capital maintained a BUY rating on IGC Pharma and raised its 12-month price target to $5.50, citing upcoming clinical milestones, AI platform development, and the Company’s expanding Alzheimer’s pipeline. In addition, IGC’s CEO and Chief Financial Officer recently increased their ownership positions through a $1.15 million debt-to-equity conversion, collectively acquiring more than 4.27 million shares and owning approximately 10% of the Company’s outstanding common stock.
With exposure to several rapidly expanding markets—including Alzheimer’s therapeutics, Artificial Intelligence, Healthcare AI, Drug Discovery, Clinical Research, and Precision Medicine—IGC Pharma continues positioning itself as a clinical-stage biotechnology company pursuing multiple value-creating catalysts.
Investors can hear directly from CEO Ram Mukunda by listening to the latest episode of The Street Reports Podcast, where he discusses the Company’s strategy, upcoming milestones, and vision for combining AI-powered healthcare with next-generation Alzheimer’s drug development. Listen to Podcast Now!